Back to School: How biopharma can reboot drug development. Access exclusive analysis here
AVGN discontinued development of its Coagulin B for hemophilia in order to focus on neurological disorders. The
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury